Gene Section
Mini Review

PAX2 (Paired box gene 2)
Ewan Robson, Jess Whall, Michael Eccles
Developmental Genetics Group, Department of Pathology, University of Otago, PO Box 913, Dunedin 9015, New Zealand (ER, JW, ME)

Published in Atlas Database: July 2005
Online updated version: http://AtlasGeneticsOncology.org/Genes/PAX2ID41642ch10q24.html
DOI: 10.4267/2042/38241

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity
Other names: Paired box homeotic gene 2
HGNC (Hugo): PAX2
Location: 10q24

Expression
PAX2 is expressed in the developing eye, ear, central nervous system (CNS), spinal cord, pancreas and urogenital tract. PAX2 contains a DNA binding paired domain, a truncated homeodomain, an octapeptide region and a carboxyl-terminal transactivation domain.

Localisation
Nuclear.

Function
PAX2 is a transcription factor that acts to regulate the expression of genes involved in mediating cell proliferation and growth, resistance to apoptosis, and cell migration. PAX2 null mutant mice die perinatally with absent cochlea, kidneys, ureters, oviducts, vas deferens and epididymis, also demonstrating mid- and hindbrain deficiency and defective optic nerve.

Homology
PAX2 shares homology through the conserved paired box domain with the other members of the nine strong PAX gene family.

Mutations
Germinal
A number of PAX2 mutations have been reported as associated with Renal Coloboma Syndrome (see below), oligomeganephronia and isolated renal hypoplasia. These are collated on the Human PAX2 Allelic Variant Database (see below).
**Somatic**

See below.

**Implicated in**

**Renal Coloboma Syndrome (RCS)**

**Note**

Caused by heterozygous PAX2 mutations. Increased apoptosis arising as a result of impaired PAX2 function believed to be responsible for disrupted nephron formation and arrested cochlear outgrowth.

**Prognosis**

Renal Coloboma Syndrome is associated with end-stage renal failure and blindness.

Various cancers, including carcinomas of the kidney, carcinomas of the prostate, carcinomas of the breast and carcinomas of the ovary. Also Wilms’ tumour and Kaposi’s sarcoma.

**Disease**

PAX2 is overexpressed in a variety of cancers (see below). A detailed understanding of the mechanistic contribution mediated by PAX2 has yet to be established. However, inhibition of PAX2 expression in a number of cancer cell lines induces cell death, indicating a role for PAX2 in tumour cell survival.

**Prognosis**

PAX2 is not expressed in normal prostate tissue or benign prostatic hyperplasia, but is expressed in primary prostatic carcinomas suggesting that PAX2 expression may be a useful marker of prostate cancer. PAX2 expression correlates with proliferation index in the majority of kidney tumour subtypes, and expression levels are significantly higher in patients presenting metastatic disease. PAX2 may therefore provide a useful prognostic marker for determining the severity of kidney cancers.

**References**


Torres M, Gómez-Pardo E, Gruss P. Pax2 contributes to inner ear patterning and optic nerve trajectory. Development. 1996 Nov;122(11):3381-91


Cai Q, Dmitrieva NI, Ferraris JD, Brooks HL, van Balkom BW, Burg M. Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):503-8

This article should be referenced as such: